{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:31:41Z","timestamp":1770798701444,"version":"3.50.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5819,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1093\/annonc\/mdh064","type":"journal-article","created":{"date-parts":[[2004,2,2]],"date-time":"2004-02-02T17:04:03Z","timestamp":1075741443000},"page":"211-217","source":"Crossref","is-referenced-by-count":67,"title":["The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, \u2018Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients\u2019"],"prefix":"10.1016","volume":"15","author":[{"given":"G.","family":"Atalay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Beex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lohrisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Lobelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Mattiaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Paridaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh064_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdh064_bb0015","first-page":"21","article-title":"Aromatase inhibitors: rationale for use following antiestrogen therapy","volume":"23","author":"Yue","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1016121822916","article-title":"Overview of the pharmacology of the aromatase inactivator exemestane","volume":"74","author":"Bruggemeier","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdh064_bb0025","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first line treatment for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized Group Efficacy and Tolerability Study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0030","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0035","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first line treatment for advanced breast cancer in postmenopausal women: results of North American Multicenter Randomized Trial","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0040","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh064_bb0045","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3816\/CBC.2000.s.004","article-title":"Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomised phase II EORTC trial with a tamoxifen control","volume":"1","author":"Paridaens","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1677\/erc.0.0060325","article-title":"Risks versus benefits in the clinical application of aromatase inhibitors","volume":"6","author":"Goss","year":"1999","journal-title":"Endocrinol Relat Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/85.12.979","article-title":"Non-cancer deaths in white adult cancer patients","volume":"85","author":"Brown","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh064_bb0060","series-title":"Harrison\u2019s Principles of Internal Medicine","first-page":"2245","article-title":"Disorders of intermediary metabolism","author":"Ginsberg","year":"2001"},{"key":"10.1093\/annonc\/mdh064_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0889-8529(05)70030-X","article-title":"Women, dyslipoproteinemia, and estrogens","volume":"27","author":"LaRosa","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1093\/annonc\/mdh064_bb0070","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"Mendelsohn","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh064_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Writing Group for the Women\u2019s Health Initiative Investigators","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1093\/annonc\/mdh064_bb0080","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdh064_bb0085","first-page":"2725","article-title":"The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property","volume":"16","author":"Elisaf","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdh064_bb0090","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomized trials","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdh064_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<100::AID-CNCR14>3.0.CO;2-5","article-title":"Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma","volume":"85","author":"Costa","year":"1999","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.20.4.1026","article-title":"Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer","volume":"20","author":"Harper-Wynne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0105","doi-asserted-by":"crossref","DOI":"10.1023\/A:1020571617274","article-title":"Effects of anastrozole on lipid metabolism compared with tamoxifen and toremifene in ovariectomized rats","volume":"76","author":"Hozumi","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdh064_bb0110","first-page":"51","article-title":"The effect of anastrozole (Arimidex) on serum lipids\u2014data from a randomized comparison of anastrozole (AN) versus tamoxifen in postmenopausal women with advanced breast cancer","volume":"64","author":"Dewar","year":"2000","journal-title":"Breast Cancer Res Treat"},{"issue":"S5","key":"10.1093\/annonc\/mdh064_bb0115","article-title":"Effect of non steroidal aromatase inhibitors (AI) on serum lipid profile in patients with breast cancer. Preliminary report","volume":"36","author":"Wojtacki","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0120","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","article-title":"Effect of letrozole on the lipid profile in postmenopausal women with breast cancer","volume":"37","author":"Elisaf","year":"2001","journal-title":"Eur J Cancer"},{"issue":"Abstr 380","key":"10.1093\/annonc\/mdh064_bb0125","first-page":"1","article-title":"The effect of aromatase inhibitor letrozole on lipid parameters in postmenopausal women with advanced breast cancer. A preliminary report","volume":"12","author":"Nicolaides","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0130","first-page":"225","article-title":"A pilot prevention study of aromatase inhibitor letrozole: effects on breast cell proliferation and bone\/lipid indices in healthy postmenopausal women","volume":"69","author":"Harper-Wynne","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"Abstr 132","key":"10.1093\/annonc\/mdh064_bb0135","first-page":"69","article-title":"The effects of exemestane on bone and lipids in the ovariectomized rat","volume":"224","author":"Goss","year":"2001","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh064_bb0140","first-page":"S107","volume":"76","author":"Goss","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdh064_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00713400","article-title":"Plasma changes in breast cancer patients during endocrine therapy\u2014lipid measurements and nuclear magnetic resonance (NMR) spectroscopy","volume":"36","author":"Engan","year":"1995","journal-title":"Breast Cancer Res Treat"},{"issue":"Abstr 167","key":"10.1093\/annonc\/mdh064_bb0150","first-page":"21","article-title":"No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane-E) in 1st line treatment of metastatic breast cancer (MBC): A companion study to European Organization of Research and Treatment of cancer (EORTC) trial 10951","volume":"43a","author":"Lohrisch","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0155","series-title":"Analysis of Messy Data","volume":"1","author":"Milliken","year":"1993"},{"key":"10.1093\/annonc\/mdh064_bb0160","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archinte.1997.00440300051004","article-title":"Triglycerides and coronary risk in women and the elderly","volume":"157","author":"LaRosa","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdh064_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1008226721932","article-title":"Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR\/BC3)","volume":"9","author":"Gershanovich","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh064_bb0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/bjc.1995.451","article-title":"Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor","volume":"72","author":"Zilembo","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdh064_bb0175","doi-asserted-by":"crossref","unstructured":"The ATAC Trialists' Group. Arimidex, tamoxifen alone or in combination. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.","DOI":"10.1016\/S0140-6736(02)09088-8"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419656267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419656267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/2\/211\/363942\/mdh064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T21:50:20Z","timestamp":1582235420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419656267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0923753419656267"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh064","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}